FORM 5
OMB APPROVAL
---------------------------------
OMB Number 3235-0362
Expires: September 30, 1998
Estimated average burden
hours per response.......... 1.0
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
|_|Check box if no longer subject to
Section 16. Form 4 or Form 5 obli-
gations may continue. See Instruc-
tion 1(b).
| |Form 3 Holdings Reported
|_|Form 4 Transactions Reported
1. Name and Address of Reporting Person*
Novartis AG
Schwarzwaldallee 215
CH-4002 Basel, Switzerland
2. Issuer Name and Ticker or Trading Symbol
Sibia Neurosciences, Inc. (SIBI)
3. IRS or Social Security Number of Reporting Person (Voluntary)
4. Statement for Month/Year
December 31, 1997
5. If Amendment, Date of Original (Month/Year)
6. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
--- ---
Officer (give title below) Other (specify below)
--- ---
------------------------------
7. Individual or Joint/Group Reporting
(check applicable line)
Form Filed by One Reporting Person
---
X Form Filed by More than One Person
---
Table I--Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
<TABLE>
<CAPTION>
1. Title of Security 2. Trans- 3. Transac- 4. Securities Acquired (A) 5. Amount of 6. Owner- 7. Nature of
(Instr. 3) action tion or Disposed of (D) Securities Bene- ship Indirect
Date Code (Instr. 3, 4 and 5) ficially Owned Form: Beneficial
(Month/ (Instr. at end of Direct Ownership
Day/ 8) Issuer's (D) or (Instr. 4)
Year) Fiscal Year Indirect
(A) (Instr. 3 and 4) (I)
or (Instr. 4)
Amount (D) Price
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Common Stock 1,035,324 I(1) (1)
<FN>
(1) These shares are owned directly by Novartis Produkte AG, a wholly owned
subsidiary of Novartis AG.
</FN>
</TABLE>
<PAGE>
TABLE II--Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
<TABLE>
<CAPTION>
1. Title of Derivative 2. Conver- 3. Trans- 4.Trans- 5. Number of 6. Date Exer- 7. Title and Amount of
Security sion or action action Derivative cisable and Underlying Securities
(Instr. 3) Exercise Date Code Securities Ac- Expiration (Instr. 3 and 4)
Price of (Month/ (Instr. 8) quired (A) or Date
Deriv- Day/ Disposed of (D) (Month/Day/
ative Year) (Instr. 3, 4 Year)
Security and 5)
Date Expira- Amount or
Exer- tion Number of
(A) (D) cisable Date Title Shares
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
</TABLE>
TABLE II--Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
(continued)
<TABLE>
<CAPTION>
8. Price of 9. Number of 10. Ownership 11. Nature of
Derivative Derivative of Derivative Indirect
Security Securities Security: Beneficial
(Instr. 5) Beneficially Direct (D) Ownership
Owned or Indirect (I) (Instr. 4)
at End of Year (Instr. 4)
(Instr. 4)
<S> <C> <C> <C>
</TABLE>
Potential persons who are to respond to the collection of information contained
in this form are not required to respond unless the form displays a currently
valid OMB number.
Novartis AG
/s/ Dr. Urs Barlocher 2/13/98
---------------------------------------- ------------------------
General Counsel Date
/s/ Christoph Mader 2/13/98
---------------------------------------- ------------------------
Senior Corporate Counsel Date
Page 2
SEC 2270 (7/96)
<PAGE>
Joint Filer Information
Name: Novartis Produkte AG
Address: Schwarzwaldallee 215
CH-4002 Basel, Switzerland
Designated Filer: Novartis AG
Issuer &
Ticker Symbol: Sibia Neurosciences, Inc. (SIBI)
Signature: NOVARTIS PRODUKTE AG
/s/ Dr. Urs Barlocher
----------------------
Authorized Signatory
/s/ Anita Buchli
----------------------
Authorized Signatory
